PurposeTo evaluate effects of intravitreal ranibizumab and bevacizumab administration on ambulatory blood pressure monitoring (ABPM) recordings in normotensive patients with age-related macular degeneration (AMD).Patients and methodsA total of 72 patients (mean age: 61.8(6.2) years, 52.8% were females) diagnosed with AMD were included in this study as divided into ranibizumab (n=34) and bevacizumab (n=38) treatment groups. Twenty-four hour, nighttime, and daytime ABMP values for systolic and diastolic BP were recorded in study groups before and after the third intravitreal injection of ranibizumab or bevacizumab.ResultsRanibizumab injection had no impact on ABPM recordings and dipping status. In the bevacizumab group, increased daytime (129.0(6.6) vs 127.7(6.6) mm Hg, P=0.002) and nighttime systolic (116.9(7.5) vs 112.6(7.1) mmHg, p<0.001) BP and decreased daytime diastolic (80.1(6.5) vs 82.4(6.1)mm Hg, P=0.001) BP were noted in the post-injection period. Also, percentage of non-dippers was significantly increased from 5.3% at pre-injection to 28.9% (P=0.004) at the post-injection period.ConclusionIn conclusion, given that it has no significant impact on ABPM recordings and dipping status, in our study, intravitreal ranibizumab injection may be the better choice in the management of AMD.

Repeated IVR did not lead to a significant change in RNFL thickness in patients with nAMD.

A 42-year-old male was admitted to our hospital because of renal impairment. He had been well until three weeks earlier when he had developed a burning pain and hazy vision in his eyes. The ophthalmologist made a diagnosis of non-granulomatous anterior uveitis and prescribed topical corticosteroid. Two weeks after therapy uveitis improved but thereafter, nausea, vomiting, fatigue, anorexia and flank pain developed. During evaluation of his symptoms, he was detected to have elevated serum creatinine and was referred to nephrology department for further assessment. His past medical history, as well as family history, were unremarkable. He denied intake of analgesics or any indigenous medicine but upon further questioning, the patient admitted to using a synthetic cannabinoid, bonsai, over the prior few weeks. The patient was not critically ill, his appetite was good and there was no recent weight loss. His blood pressure was 140/90 mmHg, pulse 98 beats/ min, temperature 37.1°C. All the peripheral pulses were normal and equally palpable. The physical examination was essentially normal; there was no evidence of infection, he had no oedema or palpable lymph nodes and organomegaly. He had no abdominal bruit. The patient also underwent an ophthalmological examination that identified fine keratic precipitations consistent with previous anterior bilateral uveitis. A Schirmer's test performed was normal. Visual acuity was unimpaired and posterior segment examination was normal [Table/ Fig-1].His biochemical test results were compatible with acute renal failure {Blood Urea Nitrogen (BUN): 41 mg/dl; creatinine 2.6 mg/ dl}. Results of liver function tests and serum calcium, phoshorus, sodium, potassium and other electrolytes were within normal limits. In his blood gas analysis mild metabolic acidosis was detected due to renal impairment (pH:7.29 mmHg HCO 3 :19.8 mmol/L); he had a normal haemogram; an elevated erythrocyte sedimentation rate of 64mm/hour, C-reactive protein 24 mg/L (normal: < 5 mg/L). Urine density and pH were within normal ranges with renal glucosuria and absence of any morphologically abnormal cells in the urine sediment. The urine culture was sterile. Complement C3 and C4 levels were within normal limits, Antinuclear (ANA) and Antineutrophil Cytoplasmic (ANCA) antibodies, anti-Glomerular Basement Membrane (GBM) antibody, antibodies to DNA, rheumatoid arthritis factor, SS-A, SS-B, RNP, Sm, Jo-1, Scl70, hepatitis B surface antigen (Hbs Ag) and hepatitis C antibody ( HCV Ab) were negative.

Patients with CFH TT genotype responded significantly better to treatment after third year, while patients with CC genotype had a poorer response to IVR.

Objectives: Spina bifida is one of the most common congenital diseases in Turkey and around the world. Despite the developing diagnostic and therapeutic methods, abnormal ocular characteristicsin spina bifida patients are still quite common. We investigated the ocular characteristics of spina bifida patients with and without hydrocephalus. Methods: We included 37 patients who were previously referred to the Istanbul Bilim University, Department of Ophthalmology and already had computed tomography (CT) scans. We retrospectively investigated the patients' ophthalmologic findings (refractive errors, strabismus, and optic disc characteristics) and used their recent CT images to measure the Evans ratios (ERs), which indirectly reflect the grade of hydrocephalus. The patients were divided into three groups according to their ERs (ER ≤ 0.3, 0.3-0.5, and ≥ 0.5), and then the ocular characteristics of these groups were compared. In addition, the patients were divided into three groups according to their ages (≤ 1 year, 1-3 years, and ≥ 3 years), and the ERs and rates of refraction defects in these groups were compared. Results: There was no relationship between specific ocular characteristics and ER or between age and ER. However, refraction errors were observed more frequently as patient age increased. Conclusions: The degree of hydrocephalus does not affect the ocular characteristics of patients with spina bifida, but emmetropization may be deteriorated in these patients.